- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
AML | Clinical
Eprenetapopt With Azacitidine Demonstrates Efficacy in TP53-Positive MDS and AML
July 23, 2021
Eprenetapop combined with azacitidine has shown positive efficacy as post-transplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia treated in a phase 2 study.
FDA Lifts Partial Clinical from Study of RVU120 in Relapsed/Refractory AML and MDS
July 15, 2021
The FDA has lifted its partial clinical hold on a phase 1B study of RVU120, which is an investigation of the agent for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Early Study of CYNK-001 Expands to Include R/R Acute Myeloid Leukemia Cohort
June 29, 2021
Patients with relapsed/refractory acute myeloid leukemia will now be assesses with the off-the-shelf cell therapy CYNK-001 after a case of conversion to minimal residual disease negativity at its highest dose level.
Early Trial Targeting CLL1-Positive Cells Demonstrates Efficacy in Pediatric AML
June 06, 2021
A small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia showed efficacy and safety with anti-C-type lectin-like molecule-based chimeric antigen receptor T cells.
Age-Related Characteristics Impact Outcomes in AML
May 27, 2021
Rajneesh Nath, MD, discusses outcomes for older patients with acute myeloid leukemia.
Remissions in Newly Diagnosed, High-Risk/Secondary AML Appear Deeper With CPX-351
May 25, 2021
Deeper remissions in patients with newly diagnosed, high-risk/secondary acute myeloid leukemia may be achieved with CPX-351 treatment and lead to improvement in overall survival, according to post hoc analyses of a phase 3 study.
Iomab-B Helps HSCT in Older AML Patients
May 20, 2021
In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed recent data from the study.
CPX-351 Demonstrates Long-Term Survival Benefits in Patients With AML
April 23, 2021
Jorge E. Cortes, MD, discusses the 5-year overall survival results of CPX-351 versus 7+3 in patients with newly diagnosed high-risk or secondary acute myeloid leukemia.
SNDX-5613 Demonstrates Robust Clinical Activity in MLL-Rearranged and NPM1c-Mutant R/R Acute Leukemia
April 21, 2021
In the phase 1/2 AUGMENT-101 clinical trial, treatment with the novel menin-MLL small molecule inhibitor SNDX-5613 led to robust clinical responses in patients with mixed lineage leukemia rearranged and NPM1c-mutant relapsed or refractory acute leukemias.
FDA Grants Orphan Drug Status to Novel IRAK4 Inhibitor in AML and MDS
April 19, 2021
The FDA has granted an orphan drug designation to CA-4948, a first-in-class, small-molecule inhibitor of IRAK4, for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.